Summary of Key Points Core Viewpoint - Vili Medical (603309) has experienced a slight decline in stock price, with a current market capitalization of 3.967 billion yuan, ranking 87th in the medical device sector and 3948th in the A-share market [1]. Company Announcements - Vili Medical announced a cash dividend of 0.2 yuan per share (before tax) for Q3 2025, with the record date set for January 7, 2026, and the payment date on January 8, 2026. The total cash dividend distribution amounts to approximately 58.37 million yuan based on a total share count of 291,871,418 shares [1][3]. - The wholly-owned subsidiary, Jiangxi Langhe Medical Device Co., Ltd., has received re-certification as a high-tech enterprise, valid for three years from October 29, 2025. This allows the subsidiary to continue benefiting from a 15% corporate income tax rate from 2025 to 2027 [2][3]. - The controlling shareholder, Gaobo Investment (Hong Kong) Co., Ltd., has released a pledge on 20 million shares, which represents 6.85% of the total share capital. As of December 31, 2025, Gaobo Investment holds 31.53% of the company's shares, with a total of 26 million shares pledged [2][3].

Core Viewpoint - The company is in the early stages of expanding its overseas business, particularly in the U.S. market, which is showing significant growth potential [1] Group 1: Business Performance - The company's U.S. business has achieved impressive performance, with revenue growth of 83.04% year-on-year in the first three quarters of 2025 [1] - The U.S. market is becoming a crucial engine for the company's international business growth [1] Group 2: Market Development - The company's overseas business is still in the early market development phase, especially in the U.S. market, which is transitioning from minimal to more substantial operations [1]